Trillium Therapeutics (TR) Receives “Market Perform” Rating from Leerink Swann

Leerink Swann reissued their market perform rating on shares of Trillium Therapeutics (TSE:TR) (NASDAQ:TRIL) in a report published on Friday morning.

Shares of TR opened at C$30.20 on Friday. Trillium Therapeutics has a 12-month low of C$28.50 and a 12-month high of C$39.45.

How to Become a New Pot Stock Millionaire

Trillium Therapeutics (TSE:TR) (NASDAQ:TRIL) last issued its quarterly earnings results on Friday, March 9th. The company reported C($0.91) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of C($1.06) by C$0.15.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.chaffeybreeze.com/2018/04/17/trillium-therapeutics-tr-receives-market-perform-rating-from-leerink-swann.html.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1).

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply